HK86588A - Composition for solid pharmaceutical preparations of active vitamins d3 and process for preparation thereof - Google Patents
Composition for solid pharmaceutical preparations of active vitamins d3 and process for preparation thereof Download PDFInfo
- Publication number
- HK86588A HK86588A HK865/88A HK86588A HK86588A HK 86588 A HK86588 A HK 86588A HK 865/88 A HK865/88 A HK 865/88A HK 86588 A HK86588 A HK 86588A HK 86588 A HK86588 A HK 86588A
- Authority
- HK
- Hong Kong
- Prior art keywords
- organic solvent
- excipient
- composition
- vitamins
- active vitamins
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65G—TRANSPORT OR STORAGE DEVICES, e.g. CONVEYORS FOR LOADING OR TIPPING, SHOP CONVEYOR SYSTEMS OR PNEUMATIC TUBE CONVEYORS
- B65G47/00—Article or material-handling devices associated with conveyors; Methods employing such devices
- B65G47/02—Devices for feeding articles or materials to conveyors
- B65G47/04—Devices for feeding articles or materials to conveyors for feeding articles
- B65G47/12—Devices for feeding articles or materials to conveyors for feeding articles from disorderly-arranged article piles or from loose assemblages of articles
- B65G47/14—Devices for feeding articles or materials to conveyors for feeding articles from disorderly-arranged article piles or from loose assemblages of articles arranging or orientating the articles by mechanical or pneumatic means during feeding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mechanical Engineering (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Furan Compounds (AREA)
Abstract
This invention is concerned with a composition for solid pharmaceutical preparations of active vitamins D<sub>3</sub>, having the remarkably improved stability of active vitamins D<sub>3</sub>. and an extremely advantageous process for the preparation thereof from the industrial viewpoint. The composition of this invention is a composition for solid pharmaceutical preparations of active vitamins D<sub>3</sub> prepared by forming an outer layer comprising active vitamins D<sub>3</sub> and an excipient, which is readily soluble in an organic solvent, around an inner layer comprising an excipient which is slightly soluble in an organic solvent.
Description
The present invention relates to a composition for solid pharmaceutical preparations of active vitamins D3 and a process for the preparation thereof. More particularly, the invention relates to a composition for solid pharmaceutical preparations of active vitamins D3 wherein the stability of said active vitamins D3 is remarkably improved and relates to a process for the preparation thereof which is very advantageous from the industrial viewpoint.
Active vitamins D3 such as 1a-hydroxycholecalciferol, 1a-25-dihydroxycholecalciferol, 1a,24-dihydroxycholecalciferol, etc. have the function of accelerating the absorption of calcium through the small intestine and promoting the resorption of calcium from the bone and accordingly they are useful in treating such diseases as osteoporosis, osteomalacia, rickets, etc.
However, since these active vitamins D3 are all labile and sensitive to heat, light, etc. and also liable to be oxidization, due care should be exercised to store them in a refrigerator, shaded place, or inert gas.
It is, therefore, a matter of primary importance to obtain a stable composition of this series of active vitamins D3 for making pharmaceutical preparations.
As a stable pharmaceutical preparations of active vitamins D3, soft capsules containing a vegetable oil solution of active vitamins D3 have hitherto been known (Japanese Patent Application Laid-Open No. 130905/'77). However, soft capsules have their particular drawbacks such as that they are limited in their form and that the process of their preparation is complicated.
As other methods of stabilizing active vitamins D3, a method of forming an inclusion compound with bile acids (Japanese Patent Application Laid-Open No. 69562/'80) and a method of forming a complex with cholesterols (Japanese Patent Application Laid-Open No. 40461/'82) are known. In these methods, the respective compositions are obtained by dissolving active vitamins D3 and bile acids or cholesterols in an organic solvent, followed by the removal of the solvent under reduced pressure.
However, disadvantages have been found with these methods in that part of the composition obtained of active vitamins D3 is resinified during the process of removing the solvent under reduced pressure, thus making the operation intricate, and in that it is difficult to obtain a composition of uniform particle size in the by pulverization after the solvent is removed. Another disadvantage due to these disadvantages is that the uniformity of the content of active vitamins D3 in the prepared drug is not satisfactory enough when formulated from the obtained composition of active vitamins D3 and other additives.
As a stabilized composition of pharmaceutical preparation, on the other hand, Japanese Patent Application Laid-Open No. 135218/'79 discloses a stabilized composition of prostaglandins E which is obtained by mixing prostaglandins E and a pharmaceutical excipient such as crystalline cellulose, which is slightly soluble in an organic solvent, in an organic solvent in the presence of an organic solvent soluble compound such as polyvinyl pyrrolidone followed by the removal of the organic solvent; however; it has no description at all as to the stabilization of such active vitamins D3 as 1a-hydroxycholecalciferol, la,25-dihydroxycholecalciferol, etc.
GB-A-1,081,667 discloses a method of producing a solid stable preparation of an active substance, which comprises finely dispersing the active substance in a physiologically acceptable cellulose derivative which is (i) soluble or colloidally dispersible in water and (ii) soluble in at least one inert solvent other than water in which the active substance is also soluble. That is, the specification discloses a substantially uniform solid composition wherein the active substance is dispersed in a cellulose derivative.
It is therefore an object of this invention to provide a composition for solid pharmaceutical preparations of active vitamins D3 wherein the stability of said active vitamins D3 is remarkably improved.
It is another object of this invention to provide a process for the preparation of a composition for solid pharmaceutical preparations of active vitamins D3 by a simple and efficient method whereby a composition uniform in size distribution and homogeneous in active vitamins D3 content can be obtained.
It is a further object of this invention to provide a composition for solid pharmaceutical preparations of active vitamins D3, wherein the stability of said active vitamins D3 to light, heat and oxidation, is remarkably improved.
It is yet another object of this invention to provide a composition of active vitamins D3 which is extremely suited for making solid preparations such as tablets, powders, granules, etc. of active vitamins D3.
Still other objects of this invention will become apparent from the following detailed description.
These objects and advantages of this invention will be attained by the composition for solid pharmaceutical preparations of active vitamins D3 and the process for the preparation thereof described hereinafter.
Thus the invention relates to a composition for solid pharmaceutical preparations of active vitamins D3 prepared by forming an outer layer comprising active vitamins D3 and an excipient which is readily soluble in an organic solvent around an inner layer comprising an excipient which is slightly soluble in an organic solvent, wherein said excipient which is readily soluble in an organic solvent is polyvinyl pyrrolidone, methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, deoxycholic acid or cholesterol, and wherein said excipient which is slightly soluble in an organic solvent is crystalline cellulose, starch, casein, cyclodextrin, lactose, hydroxypropyl starch, dextrin, or gelatin.
The invention also relates to a process for preparing a composition for solid pharmaceutical preparations of active vitamins D3 characterized by first dissolving active vitamins D3 and an excipient, which is readily suitable in an organic soluble, in an organic solvent, then adding an excipient, which is slightly soluble in an organic solvent, to the solution, followed by stirring and mixing, and thereafter removing the organic solvent from the solution, wherein said excipient which is readily soluble in an organic solvent is polyvinyl pyrrolidone, methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, deoxycholic acid or cholesterol, and wherein said excipient which is slightly soluble in an organic solvent is crystalline cellulose, starch, casein, cyclodextrin, lactose, hydroxypropyl starch, dextrin, or gelatin.
No limitations have to be specifically considered as to the kind of active vitamins D3 used in this invention and arbitrary selections may be made from any active vitamins D3. As useful active vitamins D3, such la-hydroxy vitamins D3 as 1a-hydroxycholecalciferol (Steroids, 30, 193 (1977)), 1a,-25-dihydroxycholecalciferol, (J. Org. Chem., 40, 2141 (1975)), 1a,24(R)-dihydroxycholecalciferol (U.S. Patent No. 4,022,891), la-24(S)-dihydroxycholecalciferol (U.S. Patent No. 4,022,891), and la,24,25-trihydroxy- cholecalciferol (Chem. Pharm. Bull., 23, 693 (1975)); such 24- or 25-hydroxy vitamins D3 as 25-hydroxycholecalciferol (Tetrahedron Lett., 1695 (1977)), 24-hydroxycholecalciferol (Biochemical and Biophysical Research Communications, Vol. 62, No. 2, 485, 1975), 24,25-dihydroxycholecalciferol (Tetrahedron Lett., 15, (1975)), 25,26-dihydroxycholecalciferol (Tetrahedron Lett., 1097 (1978)), and 25-hydroxy-26,26,26,27,27,27-hexafluorocholecalciferol (International Publication Number WO 83/00335); such 24-oxo vitamins D3 as 24-oxocholecalciferol (Japanese Patent Application Laid-Open No. 100055/'76), la-hydroxy-24-oxocholecalciferol (U.S. Patent No. 939,043), 25-hydroxy-24-oxocholecalciferol (U.S. Patent No. 121,857), and la,25-dihydroxy-24-oxocholecalciferol (U.S. Patent No. 121,857); and such vitamin D3-26,23-lactones as 25-hydroxycholecalciferol-26,23-lactone (J. Org. Chem., Vol. 46, No. 17, 3423, 1981 1a,25-dihydroxycholecalciferol-26,23-lactone (U.S. patent No. 4,307,231), 25-hydroxycholecalciferol-26,23-peroxylactone (Japanese Patent Application Laid-Open No. 131980/'83), and la,25-dihydroxycholecalciferol-26,23-peroxylactone (prepared in the same way as in 25-hydroxycholecalciferol-26,23-peroxylactone), for instance, may be mentioned.
The excipients, slightly soluble in an organic solvent to be used in the present invention, are crystalline cellulose, starch, casein, cyclodextrin, lactose, hydroxypropyl starch, dextrin and gelatin. These excipients may be used as a mixture of more than one. The foregoing excipients are slightly soluble in an organic solvent and yet they have a property of being water soluble or otherwise water insoluble but absorbing of water. The organic solvents to be used with the excipients, which are slightly soluble in an organic solvent, include such alcoholic solvents as methanol, ethanol, halogenated hydrocarbons such as dichloromethane, chloroform, and such ethereal solvents as diethyl ether. Of all these excipients mentioned above, crystalline cellulose, starch, casein, and cyclodextrin are desirable and crystalline cellulose is especially suited for the present purpose.
The excipients, which are readily soluble in an organic solvent, to be used for the composition in this invention, polyvinyl pyrrolidone, methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, deoxycholic acid and cholesterol. These excipients may also be used as a mixture comprising of two or more of them. The organic solvents to be used for an excipient which is readily soluble in an organic solvent mean the same organic solvents that are mentioned above. Of these excipients mentioned above, polyvinyl pyrrolidone and hydroxypropylmethyl cellulose are preferable and polyvinyl pyrrolidone is especially preferable. As for polyvinyl pyrrolidone, polyvinyl pyrrolidone having a molecular weight ranging from 250 to 1,000,000 is preferable, and polyvinyl pyrrolidone having a molecular weight of 1,000 to 700,000 is more preferable.
The composition of the present invention is prepared by forming an outer layer comprising active vitamins D3 and an excipient which is readily soluble in an organic solvent around the inner layer comprising an excipient which is slightly soluble is an organic solvent. In other word, the composition is obtained by forming a particle or a fine granule made up of an excipient which is slightly soluble in an organic solvent as an inner or core layer and then by forming an outer or crust layer made up of a mixture comprising active vitamins D3 and an excipient, which is readily soluble in an organic solvent, by allowing said mixture to adhere to or coat the inner layer. It is advisable to disperse the active vitamins D3 uniformly in the excipient, which is readily soluble in an organic solvent, in the outer layer.
The inner layer comprising an excipient which is slightly soluble in an organic solvent is a particle of a fine granule ranging from 40 to 500 pm in size and forms the core of the composition of the present invention. The composition of the present invention is made up of said core and a mixture of active vitamins D3 and an excipient which is readily soluble in an organic solvent, or a dispersion in which active vitamins D3 is dispersed in an excipient which is readily soluble in an organic solvent, wherein the mixture or dispersion is adhered to the surface of said core or coated on the core to form an outer or crust layer.
The amount of the excipient, which is readily soluble in an organic solvent, is preferably in the range of 300 to 1,000,000 times the weight active vitamins D3, and the range of 500 to 100,000 times by weight is especially preferable. The use of the excipient, which is readily soluble in an organic solvent, in vastly great quantities compared to those of the active Vitamins D3 or in the other words the use of active vitamins D3 in extremely small quantities results in the enhancement of the stability of active vitamins D3 in the present invention.
The amount of the excipient, which is slightly soluble in an organic solvent, forming the inner layer is preferably in the range of 1 to 5,000,000 times by weight the excipient, which is readily soluble in an organic solvent. Forming one of the ingredients of the outer layer, more preferably in the range of 1 to 10,000 times by weight, and especially preferably in the range of 1 to 100 times by weight.
In the case of the composition prepared according to the present invention, the stability of active vitamins D3 is much improved when said composition is made in the abovementioned form by using active vitamins D3 as a drug when compared with the case where other drugs such as prostaglandin, etc. are made into compositions of the same structure.
A composition having such structure of the present invention is prepared according to the process mentioned below. Active vitamins D3 and an excipient which is readily soluble in an organic solvent are dissolved in an organic solvent and an excipient, which is slightly soluble in an organic solvent, is admixed thereto and the solvent is thereafter distilled off to give the desired composition.
As the solvents to be used in the process, such alcoholic solvents as methanol, ethanol, and propanol; halogenated hydrocarbons such as dichloromethane and chloroform; and such ethereal solvents as diethyl ether, for instance, may be mentioned. Of these solvents mentioned above, alcoholic solvents such as methanol, ethanol are especially preferable. These organic solvents may also be used as a mixture of more than one. Active vitamins D3 and the excipient, which is readily soluble in an organic solvent, are dissolved in such an organic solvent as mentioned above. The ratio of active vitamins D3 to the excipient, which is readily soluble in an organic solvent, to be used is the same as the aforementioned ratio. The amount of an organic solvent to be used is usually 1 to 1,000 times by weight at the excipient, which is readily soluble in an organic solvent, preferably 1 to 100 times by weight. Then an excipient, which is slightly soluble in an organic solvent, is added to the obtained solution. At this time, the excipient should exist in the organic solvent as an homogeneous suspension.
As aforementioned, the amount of the excipient which is slightly soluble in an organic solvent is preferably 1 to 5,000,000 times by weight of the excipient which is readily soluble in an organic solvent, more preferably 1 to 10,000 times by weight, and most preferably 1 to 100 times by weight. After the addition of the excipient, which is slightly soluble in an organic solvent, to the solution, the admixture may be stirred thoroughly. From a consideration of maintaining the stability of active vitamins D3, the series of operations mentioned above should preferably be carried out at a low temperature or room temperature in the dark.
In the abovementioned procedures, active vitamins D3 and the excipient, which is readily soluble in an organic solvent, solidify to adhere to or cover the surface of the core comprising the excipient, which is slightly soluble in an organic solvent, thus framing the composition of the present invention having an inner layer comprising an excipient, which is slightly soluble in an organic solvent, and an outer layer comprising active vitamins D3 and an excipient, which is readily soluble in an organic solvent, formed around the said inner layer.
After the abovementioned procedure is over, the organic solvent used is removed by an appropriate method such as by spray-drying, carried out under reduced pressure or atmospheric pressure while heating. The composition for solid pharmaceutical preparations of active vitamins D3 of this invention is obtained in this way.
The abovementioned method proposed by the present invention makes it possible to obtain the desired composition having a uniform size distribution and ingredient content. The method also prevents the resinification of the composition and gives the desired composition very efficiently.
The composition thus obtained can be made into preparations directly or by addition of known excipients, lubricants, binders, coloring agents, antioxidant or corrigents. The composition of this invention can be made into a powdery preparations by suitably adjusting the particle size after the composition is mixed with other additives or directly. Also, it can be made into, tablets by use of a punch, die or press, after it is mixed with other additives or directly. Furthermore, it can be made into a granules or fine granules by pulverizing and sieving after it has been pressed into slugs. The thus obtained granules and fine granules may be used to fill gelatin hard capsules.
Known excipients other than those mentioned above are given below. As excipients, starch, crystalline cellulose, dextrin, lactose, mannitol, sorbitol, calcium phosphate anhydride. For instance, may be mentioned. As lubricants, talc, stearic acid, salt of stearic acid, wax, for instance, may be mentioned. As binders, starch, dextrin, tragacanth, gelatin, polyvinyl pyrrolidone, hydroxypropyl cellulose, polyvinyl alcohol, may be mentioned. As coloring agents, such dyestuffs derived from tar sources as Sunset Yellow, for instance, may be mentioned. As antioxidants, butyl hydroxytoluene (BHT), propyl gellate, butyl hydroxyanisol (BHA), lecithin, a-tocopherol, hydroquinone, ascorbic acid, octyl gallate, and dodecyl gallate, for instance, may be mentioned. As corrigents, citric acid, fumaric acid, menthol, and citrus perfume, for instance, may be mentioned.
The present invention is described in detail by the following examples.
1 mg of 1a-hydroxycholecalciferol (1α-OH-D3) was dissolved in 1 ml of ethanol to obtain a solution, which was then added to 100 ml of an ethanol solution in which 10 g of polyvinyl pyrrolidone (molecular weight of about 40,000) had been dissolved, and the mixture was stirred and mixed for 10 minutes. 30 g of crystalline cellulose was added to the obtained solution and the mixture was stirred and mixed for another 10 minutes. Thereafter, ethanol was distilled off under reduced pressure and the residue was dried to give 38.8 g of a composition. The content of 1α-OH-D3 in the composition was 0.0025% by weight.
This composition was stored at 40°C and the residual percentage of 1a-OH-D3 was examined as time passed. As a control, 1,000-fold corn starch powders of 1α-OH-D3 was used. This control was obtained by adding 1 g of corn starch to a solution prepared by dissolving 1 mg of 1a-OH-D3 in 10 ml of ethanol, followed by the removal of the ethanol by distillation under reduced pressure and then drying. Changes in the residual percentage of 1α-OH-D3 of the composition of this invention were examined as time passed in comparison with the control and the result is shown in Table 1. It is confirmed from Table 1 that the residual percentage of la-OH-D3 shows almost no decrease over a long period of time in the composition of the present invention in marked contrast to the control in which la-OH-D3 decomposes rapidly.
When the composition of this invention obtained in the above preparation was contacted with iodine vapor, its surface was colored yellow to brown. It is known that polyvinyl pyrrolidone reacts with iodine to form a yellow to brown compound. On the other hand, crystalline cellulose does not react with iodine at all. It is confirmed from the above fact that the outer layer of the composition of this invention is covered with polyvinyl pyrrolidone.
When the composition of this invention is subjected to ethanol extraction and the solvent was distilled off from the extract separated from the residue, polyvinyl pyrrolidone was recovered. And it was confirmed that 1a-OH-D3 was contained in the recovered polyvinyl pyrrolidone when subjected to high pressure liquid chromatography.
It has been made clear from the fact mentioned above that the composition of the present invention has crystalline cellulose as an inner layer and polyvinyl pyrrolidone as an outer layer in which 1α-OH-D3 is contained.
The compositions of the present invention were obtained according to the same method as Example 1, wherein 1 mg each of various active vitamins D3 and various excipients which are slightly soluble in the organic solvent were used. These compositions were stored at 40°C to examine the stability of active vitamins D3. Corn starch powders were also prepared as controls and the stability of active vitamins D3 contained therein was also examined likewise. The result of the examination is shown in Table 2.
The compositions, comprising 1 mg of active vitamins D3 plus 10 g each of various polyvinyl pyrrolidones (outer layer) and 30 g each of various excipients which are slightly soluble in the organic solvent (inner layer), were prepared according to Example 1. These compositions were stored at 40°C and the residual percentage of active vitamin D3 of the respective compositions was determined 1 month and 2 months later. The result is shown in Table 3.
1 mg of 1a-hydroxycholecalciferol (1α-OH-D3) was dissolved in ethanol. The resulting solution was then added to 100 ml of a mixed solvent of ethanol and dichloromethane (volume ratio 1: 1) containing 10 g of hydroxypropylmethyl cellulose (molecular weight, about 15,000) dissolved therein. This was stirred and. mixed thoroughly for 10 minutes. Further, 30 g of crystalline cellulose was added to the solution and stirred and mixed for another 10 minutes. Thereafter, ethanol and dichloromethane were distilled off under reduced pressure and dried to give 38.9 g of the desired composition. The content of 1α-OH-D3 in the composition was 0.0025% by weight.
This composition was stored at 40°C and the residual percentage of 1a-hydroxycholecalciferol was measured 1 month and 2 months later respectively. The result is shown in Table 4. As a control, the composition obtained in Example 1 was used.
The compositions were prepared according to Example 25, respectively comprising 1 mg of 1a-hydroxycholecalciferol (1α-OH-D3) plus 10 g each of various excipients readily soluble in the organic solvent (outer layer) and 30 g of crystalline cellulose (inner layer). These compositions were stored at 40°C and the residual percentage of 1a-OH-D3 was measured 1 month and 2 months later. The result is shown in Table 5.
In the same way as Example 1, 1 mg of prostaglandin E1 was dissolved in 1 ml of ethanol. The resulting solution was added to 100 ml of an ethanol solution containing 10 g of polyvinyl pyrrolidone (molecular weight, about 40,000) dissolved therein. After the mixed solution was stirred for 10 minutes, 30 g of crystalline cellulose was added thereto and the mixture was stirred for 10 minutes. Then ethanol was distilled off under reduced pressure and the residue was dried to obtain 38.7 g of a reaction product. The thermal stability of prostaglandin E1 in the reaction product was compared with the thermal stability of 1a-OH-D3 in the reaction product of Example 1 of this invention and the result is shown in Table 6. It is confirmed from Table 6 that 1a-OH-D3 contained in the composition of the present invention is stabilized while prostaglandin E1 in the reaction product prepared in the same way is not sufficiently stabilized.
Powder composed of the following additives including the composition of the present invention obtained in Example 1 was prepared and made into tablets, 7 mm in diameter and 2 mm in thickness, with the use of Erweka single punch tableting machine.
The obtained tablets contained about 1.0 ug of la-OH-D3 per tablet.
The composition of this invention obtained in Example 1 was mixed with refined sucrose and was then made into granules by admixing corn starch as a binder with the use of a sieve type granule machine. This was granules for preparation of syrups composed of the following ingredients.
This granules contained about 1.0 µg of 1a-OH-D3 per gram.
Claims (6)
1. A composition for solid pharmaceutical preparations of active vitamins D3 prepared by forming an outer layer comprising active vitamins D3 and an excipient which is readily soluble in an organic solvent around an inner layer comprising an excipient which is slightly soluble in an organic solvent, wherein said excipient which is readily soluble in an organic solvent is polyvinyl pyrrolidone, methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, deoxycholic acid or cholesterol, and wherein said excipient which is slightly soluble in an organic solvent is crystalline cellulose, starch, casein, cyclodextrin, lactose, hydroxypropyl starch, dextrin, or gelatin.
2. A composition for solid pharmaceutical preparations of active vitamins D3 according to claim 1, wherein the amount of said excipient which is readily soluble in an organic solvent is 300 to 100,000 times by weight that of active vitamins D3.
3. A composition for solid pharmaceutical preparations of active vitamins D3 according to claim 1 or 2, wherein the amount of said excipient which is slightly soluble in an organic solvent is 1 to 5,000,000 times by weight that of the excipient which is readily soluble in an organic solvent.
4. A composition for solid pharmaceutical preparations of active vitamins D3 according to any one of claims 1 to 3, wherein said active vitamins D3 are la-hydroxy vitamins D3, 24- or 25-hydroxy vitamins D3, 24-oxo vitamins D3, or vitamin 03-26,23 lactones.
5. A process for preparing a composition for solid pharmaceutical preparations of active vitamins D3 characterized by first dissolving active vitamins D3 and an excipient, which is readily soluble in an organic solvent, in an organic solvent, then adding an excipient, which is slightly soluble in an organic solvent, to the solution, followed by stirring and mixing, and thereafter removing the organic solvent from the solution, wherein said excipient which is readily soluble in an organic solvent is polyvinyl pyrrolidone, methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, deoxycholic acid or cholesterol, and wherein said excipient which is slightly soluble in an organic solvent is crystalline cellulose, starch, casein, cyclodextrin, lactose, hydroxypropyl starch, dextrin, or gelatin.
6. A process for preparing a composition for solid pharmaceutical preparations of active vitamins D3 according to claim 5, wherein said organic solvents are alcoholic solvents, halogenated hydrocarbon solvents, or ethereal solvents.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58026898A JPS59155309A (en) | 1983-02-22 | 1983-02-22 | Active type vitamin d3 composition and its preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK86588A true HK86588A (en) | 1988-11-04 |
Family
ID=12206053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK865/88A HK86588A (en) | 1983-02-22 | 1988-10-27 | Composition for solid pharmaceutical preparations of active vitamins d3 and process for preparation thereof |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4729895A (en) |
| EP (1) | EP0116755B1 (en) |
| JP (1) | JPS59155309A (en) |
| KR (1) | KR880001095B1 (en) |
| DE (1) | DE3372845D1 (en) |
| HK (1) | HK86588A (en) |
| MY (1) | MY101847A (en) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62149619A (en) * | 1985-09-05 | 1987-07-03 | Teijin Ltd | Injection composition of active type vitamin d3 |
| GB8624628D0 (en) * | 1986-10-14 | 1986-11-19 | Scras | Soluble/splitable tablets |
| JP2643222B2 (en) * | 1988-02-03 | 1997-08-20 | エーザイ株式会社 | Multi-layer granules |
| EP0390930B1 (en) * | 1988-09-26 | 1993-03-03 | Teijin Limited | Stable aqueous preparation of active vitamin d 3 |
| JP2525478B2 (en) * | 1989-03-01 | 1996-08-21 | 帝人株式会社 | Active Vitamin D with improved stability (3) Lower solid preparation |
| US5258375A (en) * | 1989-03-13 | 1993-11-02 | Ss Pharmaceutical Co., Ltd. | Composition for the preparation of dosage-form active vitamins D3 containing polyvinylacetal diethylaminoacetate |
| JP2845342B2 (en) * | 1990-04-28 | 1999-01-13 | 大正製薬株式会社 | Vitamin D Lower 3 Derivative-Containing Solid Preparation Composition |
| JPH04198129A (en) * | 1990-11-28 | 1992-07-17 | Sumitomo Pharmaceut Co Ltd | Composition containing active vitamin D↓3 types |
| US5721221A (en) * | 1991-03-08 | 1998-02-24 | Regents Of The University Of Minnesota | Lowering blood cholesterol levels using water soluble cellulose ethers |
| ES2094290T3 (en) * | 1991-04-09 | 1997-01-16 | Takeda Chemical Industries Ltd | STABILIZED PREPARATION OF VITAMIN D. |
| US5281584A (en) * | 1992-02-28 | 1994-01-25 | The Dow Chemical Company | Effect of particle-size distribution of cellulose ethers on palatability of compositions |
| US5286495A (en) * | 1992-05-11 | 1994-02-15 | University Of Florida | Process for microencapsulating cells |
| US5395627A (en) * | 1992-09-04 | 1995-03-07 | Akzo N.V. | Pharmaceutical granulate |
| IL103224A (en) * | 1992-09-18 | 1998-08-16 | Teva Pharma | Stabilized pharmaceutical compositions containing derivatives of vitamins d2 and d3 |
| US20060263428A1 (en) * | 1993-09-20 | 2006-11-23 | Eugenio Cefali | Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics |
| US6129930A (en) | 1993-09-20 | 2000-10-10 | Bova; David J. | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night |
| US6676967B1 (en) | 1993-09-20 | 2004-01-13 | Kos Pharmaceuticals, Inc. | Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia |
| US6818229B1 (en) | 1993-09-20 | 2004-11-16 | Kos Pharmaceuticals, Inc. | Intermediate release nicotinic acid compositions for treating hyperlipidemia |
| US6080428A (en) | 1993-09-20 | 2000-06-27 | Bova; David J. | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
| US6746691B2 (en) | 1993-09-20 | 2004-06-08 | Kos Pharmaceuticals, Inc. | Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics |
| AU6944796A (en) * | 1995-09-28 | 1997-04-17 | Teijin Limited | Preventive or remedy for hyperthyreosis |
| DE10127897B4 (en) * | 2001-06-08 | 2006-04-20 | Bionorica Ag | Coated tablet with dry plant extracts |
| KR100688618B1 (en) * | 2001-09-12 | 2007-03-09 | 주식회사 유유 | Sustained-release pharmaceutical composition for vitamin D oral administration |
| WO2007019418A1 (en) * | 2005-08-08 | 2007-02-15 | Sun Chemical Corporation | Ir-luminescent nanocomposite pigment and sol-gel process for manufacturing thereof |
| CA2624897C (en) * | 2005-10-12 | 2017-02-14 | Proventiv Therapeutics, Llc | Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency |
| PT3095447T (en) | 2006-02-03 | 2022-01-24 | Opko Renal Llc | Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3 |
| SI2037936T1 (en) | 2006-06-21 | 2014-11-28 | Opko Renal, Llc | Method of treating and preventing secondary hyperparathyroidism |
| EP2148684B1 (en) * | 2007-04-25 | 2013-01-16 | Cytochroma Inc. | Method of treating vitamin d insufficiency and deficiency |
| CA2835910C (en) * | 2007-04-25 | 2016-06-28 | Warner Chilcott Company, Llc | Improved vitamin d content uniformity in pharmaceutical dosage forms |
| SI2481400T1 (en) | 2007-04-25 | 2014-11-28 | Opko IP Holdings II, Inc. | Oral controlled release compositions comprising vitamin D compound and waxy carrier |
| EP3225243B1 (en) | 2007-04-25 | 2025-09-03 | Opko Renal, LLC | Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease |
| JP5647516B2 (en) * | 2007-04-25 | 2014-12-24 | シトクロマ インコーポレイテッド | Methods and compounds for vitamin D therapy |
| US20110038940A1 (en) * | 2008-02-06 | 2011-02-17 | Innov'ia | Pulverulent composition and a process for preparing the same |
| ES2593356T3 (en) | 2008-04-02 | 2016-12-07 | Opko Ireland Global Holdings, Ltd. | Useful methods, compositions, uses and kits for vitamin D deficiency and related disorders |
| LT2552484T (en) | 2010-03-29 | 2020-04-27 | Opko Ireland Global Holdings, Ltd. | METHODS AND COMPOSITIONS FOR REDUCING PARATIROID LEVELS |
| EP2468265A3 (en) * | 2010-12-04 | 2013-01-02 | DEEF Pharmaceutical Industries Co. | Homogeneous preparations containing vitamin D |
| KR101847947B1 (en) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | Stabilized modified release vitamin d formulation |
| US10220047B2 (en) | 2014-08-07 | 2019-03-05 | Opko Ireland Global Holdings, Ltd. | Adjunctive therapy with 25-hydroxyvitamin D and articles therefor |
| CN104800185B (en) * | 2015-04-22 | 2018-03-09 | 青岛正大海尔制药有限公司 | Alfacalcidol sustained release tablets and preparation method thereof |
| MY198547A (en) | 2016-03-28 | 2023-09-04 | Opko Ireland Global Holdings Ltd | Methods of vitamin d treatment |
| KR102583517B1 (en) * | 2016-12-28 | 2023-09-26 | 추가이 세이야쿠 가부시키가이샤 | Medicinal composition comprising ed-71 solid dispersion and oil dispersion |
| AU2019329905B2 (en) * | 2018-08-31 | 2024-02-01 | Opko Ireland Global Holdings, Ltd. | Vitamin D pediatric dosage forms, methods of making and using |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2691619A (en) * | 1951-09-18 | 1954-10-12 | Pfizer & Co C | Fat-soluble vitamin-containing products and process therefor |
| GB799068A (en) * | 1955-12-29 | 1958-07-30 | Hoffmann La Roche | A stabilized vitamin-d composition and a process for the production thereof |
| GB1027675A (en) * | 1963-01-07 | 1966-04-27 | Henry Joseph Johnson | Fortifying composition for water-base liquid food products |
| DE1492034A1 (en) * | 1965-05-18 | 1969-02-20 | Merck Ag E | Process for the production of solid, long-lasting preparations of sensitive active substances that are poorly soluble in water, preferably pharmaceuticals |
| GB1142147A (en) * | 1965-05-28 | 1969-02-05 | Glaxo Lab Ltd | A process for making free-flowing gel particles |
| US4016254A (en) * | 1972-05-19 | 1977-04-05 | Beecham Group Limited | Pharmaceutical formulations |
| US3957966A (en) * | 1972-05-19 | 1976-05-18 | Gaf Corporation | Stabilized vitamin food coatings |
| US3826823A (en) * | 1972-09-25 | 1974-07-30 | Syntex Inc | Stabilized prostaglandin preparations |
| JPS5418330B2 (en) * | 1973-03-16 | 1979-07-06 | ||
| JPS58401B2 (en) * | 1974-07-15 | 1983-01-06 | 明治製菓株式会社 | The antlers of the world |
| JPS5225015A (en) * | 1975-08-22 | 1977-02-24 | Sumitomo Chem Co Ltd | Process for preparing fine granular drugs |
| SE418247B (en) * | 1975-11-17 | 1981-05-18 | Haessle Ab | SET TO MAKE BODIES WITH REGULATED RELEASE OF AN ACTIVE COMPONENT |
| FR2389377A1 (en) * | 1977-05-06 | 1978-12-01 | Brohult Johan | Antiinflammatory, antirheumatic medicament - comprises 1 alpha-hydroxy-cholecalciferol |
| JPS542316A (en) * | 1977-06-07 | 1979-01-09 | Yamanouchi Pharmaceut Co Ltd | Solid pharmaceutical composition containing nifedipene |
| JPS54135218A (en) * | 1978-04-11 | 1979-10-20 | Yamanouchi Pharmaceut Co Ltd | Composition containing prostaglandin e |
| JPS5569562A (en) * | 1978-11-21 | 1980-05-26 | Teijin Ltd | Stabilization of active vitamin d3 derivative |
| US4195078A (en) * | 1979-03-09 | 1980-03-25 | Eli Lilly And Company | Nabilone granulation |
| JPS55136229A (en) * | 1979-04-10 | 1980-10-23 | Teijin Ltd | Adjustment of bone metabolism in warm-blooded animal and drug for it |
| US4301146A (en) * | 1980-07-29 | 1981-11-17 | G. D. Searle & Co. | Stabilization of 16-oxygenated prostanoic acid derivatives |
| ZA83923B (en) * | 1982-02-12 | 1983-11-30 | Hoffmann La Roche | Use of cholecalciferol derivatives |
-
1983
- 1983-02-22 JP JP58026898A patent/JPS59155309A/en active Granted
- 1983-11-18 DE DE8383307068T patent/DE3372845D1/en not_active Expired
- 1983-11-18 EP EP83307068A patent/EP0116755B1/en not_active Expired
- 1983-11-25 KR KR1019830005583A patent/KR880001095B1/en not_active Expired
-
1987
- 1987-03-16 US US07/027,082 patent/US4729895A/en not_active Expired - Lifetime
- 1987-09-18 MY MYPI87001736A patent/MY101847A/en unknown
-
1988
- 1988-10-27 HK HK865/88A patent/HK86588A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR850000238A (en) | 1985-02-26 |
| EP0116755A1 (en) | 1984-08-29 |
| JPS6360007B2 (en) | 1988-11-22 |
| EP0116755B1 (en) | 1987-08-05 |
| KR880001095B1 (en) | 1988-06-29 |
| US4729895A (en) | 1988-03-08 |
| DE3372845D1 (en) | 1987-09-10 |
| JPS59155309A (en) | 1984-09-04 |
| MY101847A (en) | 1992-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0116755B1 (en) | Composition for solid pharmaceutical preparations of active vitamins d3 and process for preparation thereof | |
| JP3464691B2 (en) | Solid pharmaceutical composition | |
| EP0413828B1 (en) | Solid preparation of active vitamin d3 having improved stability | |
| JP7062246B2 (en) | Vitamin D analog preparation and its preparation method | |
| US6531157B1 (en) | Stable emulsions and dry powders of mixtures of fat-soluble vitamins, their preparations and use | |
| EP1094841B1 (en) | Pharmaceutical levothyroxine preparation | |
| WO1992009271A1 (en) | Composition for solid pharmaceutical preparations containing active vitamins d3 and process for preparation thereof | |
| EP0387808A2 (en) | Compositions for the preparation of dosage-form active vitamins D3 and process for preparing stable dosage-form active vitamins D3 by using the same | |
| DE1492034A1 (en) | Process for the production of solid, long-lasting preparations of sensitive active substances that are poorly soluble in water, preferably pharmaceuticals | |
| US3655852A (en) | Method of forming a stable vitamin e-c granulation | |
| DE69532176T2 (en) | Tablets, capsules or granules containing desogestrel and process for their preparation | |
| JPH0640921A (en) | Activated-form vitamin d3 composition | |
| JP2914690B2 (en) | Formulation containing stable vitamin D | |
| JP2963718B2 (en) | Preparations containing vitamin D | |
| JPH0536413B2 (en) | ||
| CN109260224B (en) | Parricalcitol soft capsule and preparation method thereof | |
| US5258375A (en) | Composition for the preparation of dosage-form active vitamins D3 containing polyvinylacetal diethylaminoacetate | |
| HK1001996B (en) | Tablet, capsule, or granule comprising desogestrel and process for making them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PE | Patent expired |